Cardiovascular diseases are the number one cause of death worldwide, leading to an estimated 31 percent of all deaths. We can help change this course.
Life-threatening blood clots, if untreated, can lead to deep vein thrombosis (DVT) or pulmonary embolism (PE), conditions which affect nearly 10 million people around the world each year. People who have DVT or PE are at a higher risk of experiencing other major cardiovascular events such as heart attack, stroke and myocardial infarction, among others.
Although very effective, currently available treatments of thromboembolism are often associated with substantive bleeding risks. By expanding our understanding of ways in which patients can benefit from an established oral anticoagulant, while exploring new ways to help patients treat and prevent thrombosis, we are focused on next-generation anticoagulant assets, which are safer and equally effective.